<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A novel monoclonal antibody raised to Daudi cell membranes was found to exhibit immune stimulatory and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> properties </plain></SENT>
<SENT sid="1" pm="."><plain>The activity of this antibody (BAT) which also binds T cells was compared to that of anti-CD3 </plain></SENT>
<SENT sid="2" pm="."><plain>Anti-CD3 reacts with the T cell receptor complex, induces cell proliferation, and cytolytic activity in vitro and also manifests in vivo anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effect against murine <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Comparison of the two antibodies demonstrates similar induction in vitro of splenocyte proliferation and cytolytic activity </plain></SENT>
<SENT sid="4" pm="."><plain>Both BAT and anti-CD3 antibodies manifest anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity in mice bearing B16 <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>They differ however in the timing of antibody administration post-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation which is most effective in eliciting the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effect </plain></SENT>
<SENT sid="6" pm="."><plain>Whereas BAT is most effective when administered 10 to 14 days post-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation, anti-CD3 is effective at an early time </plain></SENT>
<SENT sid="7" pm="."><plain>Data also indicate that BAT synergises with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in eliciting cell proliferation in vitro </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, this effect could not be demonstrated with anti-CD3 </plain></SENT>
<SENT sid="9" pm="."><plain>The properties of BAT may be of advantage in its potential clinical use </plain></SENT>
</text></document>